{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:39:05Z","timestamp":1791347945338,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"DOI":"10.1245\/s10434-026-20397-7","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:27:01Z","timestamp":1791048421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lack of Utility of Ki-67 in Axillary Surgical Planning and Prognostication after Neoadjuvant Chemotherapy for Node-Positive Breast Cancer"],"prefix":"10.1245","author":[{"given":"Katherine","family":"Fleshner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farin","family":"Amersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mirocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando E.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa K.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"11","key":"20397_CR1","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(11):4515\u201322. https:\/\/doi.org\/10.1245\/s10434-020-08650-z.","journal-title":"Ann Surg Oncol."},{"issue":"21","key":"20397_CR2","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","volume":"392","author":"EP Mamounas","year":"2025","unstructured":"Mamounas EP, Bandos H, White JR, et al. Omitting regional nodal irradiation after response to neoadjuvant chemotherapy. N Engl J Med. 2025;392(21):2113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2414859.","journal-title":"N Engl J Med."},{"issue":"12","key":"20397_CR3","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492.","journal-title":"Clin Cancer Res."},{"key":"20397_CR4","doi-asserted-by":"publisher","unstructured":"I-SPY2 Trial Consortium. Association of event-free and distant recurrence\u2013free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020;6(9):1355-1362. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2535","DOI":"10.1001\/jamaoncol.2020.2535"},{"issue":"22","key":"20397_CR5","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med."},{"issue":"7","key":"20397_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med."},{"issue":"11","key":"20397_CR7","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374. https:\/\/doi.org\/10.1245\/s10434-016-5246-8.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20397_CR8","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/bcr3679","volume":"16","author":"P Maisonneuve","year":"2014","unstructured":"Maisonneuve P, Disalvatore D, Rotmensz N, et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014;16(3):R65. https:\/\/doi.org\/10.1186\/bcr3679.","journal-title":"Breast Cancer Res."},{"issue":"34","key":"20397_CR9","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514.","journal-title":"J Clin Oncol."},{"issue":"7","key":"20397_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2020","unstructured":"Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. JNCI J Natl Cancer Inst. 2020;113(7):808\u201319. https:\/\/doi.org\/10.1093\/jnci\/djaa201.","journal-title":"JNCI J Natl Cancer Inst."},{"issue":"9","key":"20397_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/jcp.39.9.977","volume":"39","author":"J Gerdes","year":"1986","unstructured":"Gerdes J, Lelle RJ, Pickartz H, et al. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol. 1986;39(9):977\u201380. https:\/\/doi.org\/10.1136\/jcp.39.9.977.","journal-title":"J Clin Pathol."},{"issue":"12","key":"20397_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1159\/000517490","volume":"99","author":"A de Gregorio","year":"2021","unstructured":"de Gregorio A, Friedl TWP, Hering E, et al. Ki67 as proliferative marker in patients with early breast cancer and its association with clinicopathological factors. Oncology. 2021;99(12):780\u20139. https:\/\/doi.org\/10.1159\/000517490.","journal-title":"Oncology."},{"issue":"1","key":"20397_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s13104-019-4653-x","volume":"12","author":"AA Hashmi","year":"2019","unstructured":"Hashmi AA, Hashmi KA, Irfan M, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019;12(1):605. https:\/\/doi.org\/10.1186\/s13104-019-4653-x.","journal-title":"BMC Res Notes."},{"issue":"1","key":"20397_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00000658-200201000-00003","volume":"235","author":"AN Mirza","year":"2002","unstructured":"Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;235(1):10.","journal-title":"Ann Surg."},{"issue":"10","key":"20397_CR15","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","volume":"96","author":"E de Azambuja","year":"2007","unstructured":"de Azambuja E, Cardoso F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96(10):1504\u201313. https:\/\/doi.org\/10.1038\/sj.bjc.6603756.","journal-title":"Br J Cancer."},{"issue":"3","key":"20397_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-015-3559-0","volume":"153","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477\u201391. https:\/\/doi.org\/10.1007\/s10549-015-3559-0.","journal-title":"Breast Cancer Res Treat."},{"key":"20397_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00069","author":"F Andre","year":"2026","unstructured":"Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO.22.00069.","journal-title":"J Clin Oncol."},{"issue":"7","key":"20397_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMoa2302344","volume":"389","author":"TJ Whelan","year":"2023","unstructured":"Whelan TJ, Smith S, Parpia S, et al. Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N Engl J Med. 2023;389(7):612\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2302344.","journal-title":"N Engl J Med."},{"issue":"4","key":"20397_CR19","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1245\/s10434-022-12972-5","volume":"30","author":"KK Hunt","year":"2023","unstructured":"Hunt KK, Suman VJ, Wingate HF, et al. Local-regional recurrence after neoadjuvant endocrine therapy: data from ACOSOG Z1031 (Alliance), a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer. Ann Surg Oncol. 2023;30(4):2111\u20138. https:\/\/doi.org\/10.1245\/s10434-022-12972-5.","journal-title":"Ann Surg Oncol."},{"issue":"19","key":"20397_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/jnci\/djn309","volume":"100","author":"MJ Ellis","year":"2008","unstructured":"Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor\u2013positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380\u20138. https:\/\/doi.org\/10.1093\/jnci\/djn309.","journal-title":"J Natl Cancer Inst."},{"key":"20397_CR21","doi-asserted-by":"publisher","first-page":"101432","DOI":"10.1016\/j.lanepe.2025.101432","volume":"58","author":"MA Toli","year":"2025","unstructured":"Toli MA, Liu X, Massa D, et al. Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study. Lancet Reg Health - Eur. 2025;58:101432. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101432.","journal-title":"Lancet Reg Health - Eur."},{"issue":"4","key":"20397_CR22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","volume":"2","author":"SS Mougalian","year":"2016","unstructured":"Mougalian SS, Hernandez M, Lei X, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol. 2016;2(4):508\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4935.","journal-title":"JAMA Oncol."},{"key":"20397_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13000-017-0608-5","volume":"12","author":"B \u00c1cs","year":"2017","unstructured":"\u00c1cs B, Z\u00e1mb\u00f3 V, V\u00edzkeleti L, et al. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol. 2017;12:20. https:\/\/doi.org\/10.1186\/s13000-017-0608-5.","journal-title":"Diagn Pathol."},{"issue":"3","key":"20397_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-023-07152-2","volume":"203","author":"D Moldoveanu","year":"2024","unstructured":"Moldoveanu D, Hoskin TL, Day CN, Schulze AK, Goetz MP, Boughey JC. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+\/Her2\u2212 breast cancer. Breast Cancer Res Treat. 2024;203(3):419\u201328. https:\/\/doi.org\/10.1007\/s10549-023-07152-2.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"20397_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13\u201321. https:\/\/doi.org\/10.1200\/JCO.2014.57.0572.","journal-title":"J Clin Oncol."},{"issue":"15","key":"20397_CR26","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804. https:\/\/doi.org\/10.1200\/JCO.2011.38.8595.","journal-title":"J Clin Oncol."},{"issue":"10","key":"20397_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA."},{"issue":"4","key":"20397_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/SLA.0000000000005671","volume":"277","author":"NA Che Bakri","year":"2023","unstructured":"Che Bakri NA, Kwasnicki RM, Khan N, et al. Impact of axillary lymph node dissection and sentinel lymph node biopsy on upper limb morbidity in breast cancer patients. Ann Surg. 2023;277(4):572\u201380. https:\/\/doi.org\/10.1097\/SLA.0000000000005671.","journal-title":"Ann Surg."},{"issue":"3","key":"20397_CR29","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.bjps.2022.01.006","volume":"75","author":"M Coriddi","year":"2022","unstructured":"Coriddi M, Kim L, McGrath L, Mehrara B, Dayan J. Immediate lymphatic reconstruction: Outcomes of a single-institution pilot study. J Plast Reconstr Aesthet Surg. 2022;75(3):1261\u201382. https:\/\/doi.org\/10.1016\/j.bjps.2022.01.006.","journal-title":"J Plast Reconstr Aesthet Surg."},{"key":"20397_CR30","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.breast.2015.07.017","volume":"24","author":"C Denkert","year":"2015","unstructured":"Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast. 2015;24:S67\u201372. https:\/\/doi.org\/10.1016\/j.breast.2015.07.017.","journal-title":"Breast."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20397-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20397-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20397-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:27:01Z","timestamp":1791048421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20397-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":30,"alternative-id":["20397"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20397-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflicts of interest or other disclosures.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}